Deutsche Bank said in a research note on Tuesday that investor sentiment in the drug supply chain is as bad as it can ever be.
However, the firm maintains its Buy rating on Walgreens Boots Alliance Inc (NASDAQ: WBA), as it views it as one company in the drug supply chain where it expects
strategy and execution to drive improvement in earnings per share.
The company is due to release its fiscal year fourth-quarter results before the markets open on Thursday.
F4Q Expectations
Analyst George Hill estimates earnings of $0.98 per share, in the middle of the implied guidance of $0.93–$1.03. Hill said he
expects the results to reflect slow seasonality, exit of the Russian drug distribution business, a negative pound exchange rate and
a full quarter of 15 percent ownership in AmerisourceBergen Corp. (NYSE: ABC) shares.
FY17 Guidance
While noting that investors are below-consensus on their fiscal year 2017 earnings per share estimate, Deutsche Bank is of the
view that $4.85–$4.90 could be viewed with relief. Despite being positive on Walgreen's recent PBM partnerships, the firm said
pricing concessions could offset volume gains in the first year. Estimating 10–15 cents contribution from Tricare pharmacy
relationship in 2017 and 18 cents from a full year ownership of 24 percent of Amerisource, the firm expects 2017 earnings per share
of $5.03, in line with the consensus estimate.
Focus During Conference Call
The firm believes answers will sought for questions on Rite Aid Corporation (NYSE: RAD) transaction process, drug and pharmacy pricing and the recent PBM partnerships
announced by Walgreens.
As such, the firm maintains its Buy rating on the shares of the company with its price target at $94.
At last check, shares of Walgreens Boots Alliance were up 0.06 percent at $78.06.
Full ratings
data available on Benzinga Pro.
Do you have ideas for articles/interviews you'd like to see more of on Benzinga? Please email feedback@benzinga.com with your best article ideas. One person will be randomly selected to win
a $20 Amazon gift card!
Latest Ratings for ABC
Date |
Firm |
Action |
From |
To |
Oct 2016 |
UBS |
Initiates Coverage on |
|
Neutral |
Oct 2016 |
Avondale Partners |
Upgrades |
Market Perform |
Market Outperform |
Aug 2016 |
Barclays |
Maintains |
|
Equal-Weight |
View More Analyst Ratings for
ABC
View the Latest Analyst Ratings
© 2016 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.